Dr Reddy's buys UCB portfolio in S Asia
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories has snapped up a select portfolio of UCB's established products business in India, Nepal, Sri Lanka and Maldives for INR8bn ($128m), bolstering its presence in the high growth dermatology, respiratory and paediatric segments.
You may also be interested in...
Flurry Of Marketing Collaborations Set India Deal Street Abuzz
In-licensing and co-marketing/co-promotion deals are on the up in India, as local and foreign companies tango together to reach more patients and expand their business in the country's competitive market. Lupin-Boehringer, Dr Reddy’s-UCB and Glenmark-Helsinn are among the recent companies doing deals in the area.
M&A Trends: Private Equity And 'Aspirational' Execs Pair Up In India
Private equity firms partnering with senior management professionals bitten by the entrepreneurial bug to buy pharmaceutical businesses in India were some of the emerging trends highlighted by experts at a recent CPhI congress in Mumbai. Scrip covers the key conference highlights on the "maturing" Indian M&A market, including how foreign firms are shedding their older portfolios to reallocate resources to newer products.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.